2.11. In Vitro HPLC Analysis of DE The samples of DE in vitro experiments were analyzed using an HPLC system consisting of a system controller (SCL-10 ATVP; Shimadzu, Japan), a binary pump (LC-10 ATVP, Shimadzu), a UV-VIS detector (SPD-10 AVP, Shimadzu), a column oven, and an autoinjector (SIL-10A, Shimadzu). The separation method was under the www.selleckchem.com/products/Paclitaxel(Taxol).html following conditions: C18 reversed phase analytical Inhibitors,research,lifescience,medical column (4.6 × 150mm2, 5μm, Shim-pack VP-ODS). The mobile phase was 60:40 (v/v) methanol-ammonium acetate buffer (0.05M, pH 4.0), column temperature of 40°C, UV detective wavelength of 257nm, flow rate of 1.0mL/min, and injection volume of 10μL. The data were acquired
and analyzed by Shimadzu Inhibitors,research,lifescience,medical Class-VP chromatography software. There was no interference from skin and a well-separated peak was detected at the retention time of 9.1 ± 0.1min with the sensitivity of 0.02μg/mL. The peak area correlated linearly with DE concentration in the range from 1 to 500μg/mL. 2.12. In Vivo UPLC-MS/MS Analysis of DE The analyte was recovered from plasma samples by liquid-liquid extraction (LLE) after thawed thoroughly at room temperature . A 100μL aliquot of plasma, 10μL ibuprofen (1μg/mL) as internal standard (IS), and 10μL 0.1 HCl (1mol/L) were pipetted into 1.5mL centrifuge tubes. Samples were extracted using 1mL ethyl acetate and the tubes were vortexed for 2min prior Inhibitors,research,lifescience,medical to centrifugation
at 17,800×g for 3min. Then 800μL supernatant from each centrifuge tube was pipetted into sample insert and evaporated to dryness completely at 40°C with a vacuum centrifugal concentrator (miVac Inhibitors,research,lifescience,medical DUO, Genevac). Samples were then reconstituted with 200μL 50:50 (v/v) methanol-water, the sample vials were vortexed for a further 1min and centrifuged
at 17,800×g for 3min, and then the supernatants were used for analysis. Analysis of DE and plasma was performed with UPLC-MS/MS system equipped with a system controller (SCL-10 ATVP; Shimadzu), a binary pump (LC-10 ATVP; Shimadzu), a UV-VIS detector (SPD-10 AVP, Shimadzu), a column oven, and an Inhibitors,research,lifescience,medical auto injector (SIL-10A; Shimadzu) with an electrospray ionization (ESI) interface. The UPLC separation method was under the following conditions: C18 reversed phase analytical column (Shim-pack XR-ODS) (2.0 I.D. × 75mm2, 1.6μm), mobile phase of methanol and 10mM ammonium acetate buffer, column temperature of 40°C, detective wavelength Journal of Clinical Oncology of 257nm, flow rate of 0.3mL/min, and injection volume of 5μL (see Table 5). A gradient elution was carried out using a mobile phase consisted of a mixture of A (10mM ammonium acetate buffer) and B (methanol) at a flow rate of 0.3mL/min according to the following multistep gradients shown in Tables Tables22 and and33. Table 2 Composition of the formulation for optimization (a). Table 3 Composition of the formulation for optimization (b). Table 5 Gradient conditions for UPLC.